Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Sara Pellegrino - Senior Vice President, Investor & Public Relations & Corporate Communications Fred Vogt - Interim President & Chief Executive Officer Igor Bilinsky - Chief Operating Officer Jim Ziegler - Executive Vice President, Commercial Friedrich Finckenstein - Chief Medical Officer Jean-Marc Bellemin - Chief Financial Officer Conference Call Participants Peter Lawson - Barclays ...

1 I OVANCE 1 Corporate Overview May 2022 © 2022, Iovance Biotherapeutics, Inc. Forward-Looking Statements Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). All such written or oral statements made in this presentation, other than statements of historical fact, are forward-looking statements an ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2022 Results Conference Call May 5, 2022 4:30 PM ET Company Participants Sara Pellegrino - Vice President, Investor and Public Relations Dr. Fred Vogt - Interim President and Chief Executive Officer Dr. Igor Bilinsky - Chief Operating Officer Jim Ziegler - Senior Vice President, Commercial Dr. Friedrich Finckenstein - Chief Medical Officer Dr. Madan Jagasia - Senior Vice President, Medical Affairs Jean-Marc Bellemin - Chief Financial Officer Dr. Raj Puri - Exec ...

1 I OVANCE 1 Corporate Overview March 2022 © 2022, Iovance Biotherapeutics, Inc. Forward-Looking Statements Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). All such written or oral statements made in this presentation, other than statements of historical fact, are forward-looking statements ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Sara Pellegrino – Vice President, Investor and Public Relations Fred Vogt – Interim President and Chief Executive Officer Igor Bilinsky – Chief Operating Officer Jim Ziegler – Senior Vice President, Commercial Friedrich Finckenstein – Chief Medical Officer Jean-Marc Bellemin – Chief Financial Officer Conference Call Participants Tyler Van Buren – Cowen Michael Yee – Jefferies Peter ...

| --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | 1 Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). All such written or oral statements made in this presentation, other than statements of historical fact, are forwar ...

| --- | --- | --- | --- | --- | |-------------------------------------------|-------------------------------------------------------------------------|-------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Conference Call & Webcast: Annual Meeting | Clinical Data Highlights at Society for Immunotherapy of Cancer (SITC) | | | | | | | November 13, 2021 | | | | | © 2021, Iovance Biotherapeutics, Inc | | | | 1 Certain matters discussed in this presentation are "forward-looking st ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Sara Pellegrino – Vice President, Investor Relations & Public Relations Fred Vogt – Interim President and Chief Executive Officer Igor Bilinsky – Chief Operating Officer Jim Ziegler – Senior Vice President, Commercial Friedrich Finckenstein – Chief Medical Officer Jean-Marc Bellemin – Chief Financial Officer Conference Call Participants Mara Goldstein – Mizuho Michael Yee – Jefferies ...

Start Time: 16:30 January 1, 0000 5:12 PM ET Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2021 Earnings Conference Call August 05, 2021, 16:30 PM ET Company Participants Frederick Vogt - Interim President and CEO Igor Bilinsky - COO Jim Zigler - SVP, Commercial Friedrich Finckenstein - CMO Jean-Marc Bellemin - CFO Madan Jagasia - SVP of Medical Affairs Sara Pellegrino - VP, Investor and Public Relations Conference Call Participants Michael Yee - Jefferies Mark Breidenbach - Oppenheimer Benjamin Burnett - ...

ASCO Update Call June 6, 2021 © 2021, Iovance Biotherapeutics, Inc 1 | --- | --- | |---------------------------------------------------------------------------------------------------------------------------|-------------------------| | Agenda | | | | | | • Corporate Update : Fred Vogt, incoming Interim CEO and President • ASCO Updates for Lifileucel in Advanced Melanoma | : Omid Hamid, MD, Chief | | of Research/Immuno-Oncology, The Angeles Clinic & Research Institute | | | • Financial Summary : Jean-Marc B ...